Liposomal Amphotericin B and HIV-Associated Visceral Leishmaniasis

[1]  S. Antinori,et al.  A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience. , 2004, The Journal of antimicrobial chemotherapy.

[2]  F. Laguna.  Treatment of leishmaniasis in HIV-positive patients , 2003, Annals of tropical medicine and parasitology.

[3]  S. Sundar,et al.  Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  S. Sundar,et al.  Advances in the treatment of leishmaniasis , 2002, Current opinion in infectious diseases.

[5]  C. Bagnis,et al.  Amphotericin B nephrotoxicity. , 2002, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[6]  P. Melby.  Recent developments in leishmaniasis , 2002, Current opinion in infectious diseases.

[7]  K. Garey,et al.  A Prospective and Retrospective Analysis of the Nephrotoxicity and Efficacy of Lipid‐Based Amphotericin B Formulations , 2001, Pharmacotherapy.

[8]  J. H. Quero,et al.  Tratamiento de la coinfección VIH-leishmaniasis visceral con un nuevo régimen de anfotericina B liposomal (AMB-L) , 2001 .